1160755-11-2

Basic information

• Product Name: ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester
• Synonyms: ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester
• CAS NO: 1160755-11-2
• Molecular Weight: 265.312
• Mol File: 1160755-11-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester(1160755-11-2)
• EPA Substance Registry System: ((S)-4-amino-4-carbamoylbutyl)carbamic acid benzyl ester(1160755-11-2)

Safety Data

• Hazardous Substances Data: 1160755-11-2(Hazardous Substances Data)

Upstream product

• 2480-93-5 Boc-Orn(Z)-OH 
• 62631-17-8 Methyl N-δ-benzyloxycarbonyl-L-ornithinate 

Downstream Products

• 1160939-75-2 3,5-diamino-6-chloropyrazine-2-carboxylic acid [(S)-4-(3-phenylacetylaminopropyl)imidazolidin-(2E)-ylidene]amide 
• 1160939-74-1 3,5-diamino-6-chloropyrazine-2-carboxylic acid [(S)-4-(3-phenylmethanesulfonylaminopropyl)-imidazolidin-(2E)-ylidene]amide 
• 1160939-73-0 3,5-diamino-6-chloropyrazine-2-carboxylic acid [(S)-4-[3-(3-benzylureido)-propyl]-imidazolidin-(2E)-ylidene]-amide 
• 1160939-71-8 (3-{(S)-2-[(E)-3,5-diamino-6-chloropyrazine-2-carbonylimino]imidazolidin-4-yl}propyl)carbamic acid benzyl ester 
• 1160755-10-1 ((S)-4,5-diaminopentyl)carbamic acid benzyl ester 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.